1
|
Feng W, Zhang Y, Ding S, Chen S, Wang T, Wang Z, Zou Y, Sheng C, Chen Y, Pang Y, Marshall C, Shi J, Nedergaard M, Li Q, Xiao M. B lymphocytes ameliorate Alzheimer's disease-like neuropathology via interleukin-35. Brain Behav Immun 2023; 108:16-31. [PMID: 36427805 DOI: 10.1016/j.bbi.2022.11.012] [Citation(s) in RCA: 15] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/14/2022] [Revised: 10/28/2022] [Accepted: 11/19/2022] [Indexed: 11/26/2022] Open
Abstract
Increasing evidence supports the involvement of the peripheral immune system in the pathogenesis of Alzheimer's disease (AD). In the present study, we found that B lymphocytes could mitigate beta-Amyloid (Aβ) pathology and memory impairments in a transgenic AD mouse model. Specifically, in young 5 × FAD mice, we evidenced increased B cells in the frontal cortex and meningeal tissues; depletion of mature B cells aggravated these mice's Aβ load and memory deficits. The increased B cells produced more interleukin-35 (IL-35) in the front cortex. We further found IL-35 neutralization exacerbated Aβ pathology, while injecting IL-35 mitigated Aβ load and cognitive dysfunction in 5 × FAD mice with or without mature B cell deficiency. Mechanistically, IL-35 inhibited neuronal BACE1 transcription through modulating the SOCS1/STAT1 pathway, and reduced Aβ production accordingly. Reanalysis of the single-cell RNA sequencing data from blood samples of AD patients suggested an increased population of IL-35-producing B cells. Together, the present study revealed a novel effect of B lymphocyte-derived IL-35 on inhibiting Aβ production in the frontal cortex, which may serve as a potential target for future AD treatment.
Collapse
Affiliation(s)
- Weixi Feng
- Jiangsu Key Laboratory of Neurodegeneration, Nanjing Medical University, Nanjing 211166, China; Center for Global Health, Nanjing Medical University, Nanjing 211166, China.
| | - Yanli Zhang
- Jiangsu Key Laboratory of Neurodegeneration, Nanjing Medical University, Nanjing 211166, China; Brain Institute, Nanjing Brain Hospital, Nanjing Medical University, Nanjing 210029, China
| | - Shixin Ding
- Jiangsu Key Laboratory of Neurodegeneration, Nanjing Medical University, Nanjing 211166, China; Center for Global Health, Nanjing Medical University, Nanjing 211166, China
| | - Sijia Chen
- Jiangsu Key Laboratory of Neurodegeneration, Nanjing Medical University, Nanjing 211166, China; Brain Institute, Nanjing Brain Hospital, Nanjing Medical University, Nanjing 210029, China
| | - Tianqi Wang
- Jiangsu Key Laboratory of Neurodegeneration, Nanjing Medical University, Nanjing 211166, China; Center for Global Health, Nanjing Medical University, Nanjing 211166, China
| | - Ze Wang
- Jiangsu Key Laboratory of Neurodegeneration, Nanjing Medical University, Nanjing 211166, China; Brain Institute, Nanjing Brain Hospital, Nanjing Medical University, Nanjing 210029, China
| | - Ying Zou
- Jiangsu Key Laboratory of Neurodegeneration, Nanjing Medical University, Nanjing 211166, China; Brain Institute, Nanjing Brain Hospital, Nanjing Medical University, Nanjing 210029, China
| | - Chengyu Sheng
- Jiangsu Key Laboratory of Neurodegeneration, Nanjing Medical University, Nanjing 211166, China; Center for Global Health, Nanjing Medical University, Nanjing 211166, China
| | - Yan Chen
- Jiangsu Key Laboratory of Neurodegeneration, Nanjing Medical University, Nanjing 211166, China; Center for Global Health, Nanjing Medical University, Nanjing 211166, China
| | - Yingting Pang
- Jiangsu Key Laboratory of Neurodegeneration, Nanjing Medical University, Nanjing 211166, China; Brain Institute, Nanjing Brain Hospital, Nanjing Medical University, Nanjing 210029, China
| | - Charles Marshall
- Department of Physical Therapy, University of Kentucky Center of Excellence in Rural Health, Hazard, KY, USA
| | - Jingping Shi
- Brain Institute, Nanjing Brain Hospital, Nanjing Medical University, Nanjing 210029, China
| | - Maiken Nedergaard
- Center for Translational Neuromedicine, Department of Neurosurgery, University of Rochester Medical Center, Rochester, NY 14642, USA
| | - Qian Li
- Jiangsu Key Laboratory of Neurodegeneration, Nanjing Medical University, Nanjing 211166, China; Center for Global Health, Nanjing Medical University, Nanjing 211166, China.
| | - Ming Xiao
- Jiangsu Key Laboratory of Neurodegeneration, Nanjing Medical University, Nanjing 211166, China; Center for Global Health, Nanjing Medical University, Nanjing 211166, China; Brain Institute, Nanjing Brain Hospital, Nanjing Medical University, Nanjing 210029, China.
| |
Collapse
|
2
|
Transgenic Animals for the Generation of Human Antibodies. LEARNING MATERIALS IN BIOSCIENCES 2021. [DOI: 10.1007/978-3-030-54630-4_5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
|
3
|
Teng Y, Young JL, Edwards B, Hayes P, Thompson L, Johnston C, Edwards C, Sanders Y, Writer M, Pinto D, Zhang Y, Roode M, Chovanec P, Matheson L, Corcoran AE, Fernandez A, Montoliu L, Rossi B, Tosato V, Gjuracic K, Nikitin D, Bruschi C, McGuinness B, Sandal T, Romanos M. Diverse human V H antibody fragments with bio-therapeutic properties from the Crescendo Mouse. N Biotechnol 2019; 55:65-76. [PMID: 31600579 DOI: 10.1016/j.nbt.2019.10.003] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2019] [Revised: 09/04/2019] [Accepted: 10/04/2019] [Indexed: 01/26/2023]
Abstract
We describe the 'Crescendo Mouse', a human VH transgenic platform combining an engineered heavy chain locus with diverse human heavy chain V, D and J genes, a modified mouse Cγ1 gene and complete 3' regulatory region, in a triple knock-out (TKO) mouse background devoid of endogenous immunoglobulin expression. The addition of the engineered heavy chain locus to the TKO mouse restored B cell development, giving rise to functional B cells that responded to immunization with a diverse response that comprised entirely 'heavy chain only' antibodies. Heavy chain variable (VH) domain libraries were rapidly mined using phage display technology, yielding diverse high-affinity human VH that had undergone somatic hypermutation, lacked aggregation and showed enhanced expression in E. coli. The Crescendo Mouse produces human VH fragments, or Humabody® VH, with excellent bio-therapeutic potential, as exemplified here by the generation of antagonistic Humabody® VH specific for human IL17A and IL17RA.
Collapse
Affiliation(s)
- Yumin Teng
- Crescendo Biologics Ltd, Babraham Research Campus, Cambridge, CB22 3AT, UK.
| | - Joyce L Young
- Crescendo Biologics Ltd, Babraham Research Campus, Cambridge, CB22 3AT, UK
| | - Bryan Edwards
- Crescendo Biologics Ltd, Babraham Research Campus, Cambridge, CB22 3AT, UK
| | - Philip Hayes
- Crescendo Biologics Ltd, Babraham Research Campus, Cambridge, CB22 3AT, UK
| | - Lorraine Thompson
- Crescendo Biologics Ltd, Babraham Research Campus, Cambridge, CB22 3AT, UK
| | - Colette Johnston
- Crescendo Biologics Ltd, Babraham Research Campus, Cambridge, CB22 3AT, UK
| | - Carolyn Edwards
- Crescendo Biologics Ltd, Babraham Research Campus, Cambridge, CB22 3AT, UK
| | - Yun Sanders
- Crescendo Biologics Ltd, Babraham Research Campus, Cambridge, CB22 3AT, UK
| | - Michele Writer
- Crescendo Biologics Ltd, Babraham Research Campus, Cambridge, CB22 3AT, UK
| | - Debora Pinto
- Crescendo Biologics Ltd, Babraham Research Campus, Cambridge, CB22 3AT, UK
| | - Yanjing Zhang
- Crescendo Biologics Ltd, Babraham Research Campus, Cambridge, CB22 3AT, UK
| | - Mila Roode
- Crescendo Biologics Ltd, Babraham Research Campus, Cambridge, CB22 3AT, UK
| | - Peter Chovanec
- Babraham Institute, Babraham Research Campus, Cambridge, CB22 3AT, UK
| | - Louise Matheson
- Babraham Institute, Babraham Research Campus, Cambridge, CB22 3AT, UK
| | - Anne E Corcoran
- Babraham Institute, Babraham Research Campus, Cambridge, CB22 3AT, UK
| | - Almudena Fernandez
- Centro Nacional de Biotecnologia (CNB-CSIC) & CIBER de Enfermedades Raras (CIBERER-ISCIII), Darwin 3, 28049, Madrid, Spain
| | - Lluis Montoliu
- Centro Nacional de Biotecnologia (CNB-CSIC) & CIBER de Enfermedades Raras (CIBERER-ISCIII), Darwin 3, 28049, Madrid, Spain
| | - Beatrice Rossi
- International Centre for Genetic Engineering and Biotechnology, Yeast Molecular Genetics Laboratory, Padriciano 99, 34149, Trieste, Italy
| | - Valentina Tosato
- International Centre for Genetic Engineering and Biotechnology, Yeast Molecular Genetics Laboratory, Padriciano 99, 34149, Trieste, Italy
| | - Kresimir Gjuracic
- International Centre for Genetic Engineering and Biotechnology, Yeast Molecular Genetics Laboratory, Padriciano 99, 34149, Trieste, Italy
| | - Dmitri Nikitin
- International Centre for Genetic Engineering and Biotechnology, Yeast Molecular Genetics Laboratory, Padriciano 99, 34149, Trieste, Italy
| | - Carlo Bruschi
- International Centre for Genetic Engineering and Biotechnology, Yeast Molecular Genetics Laboratory, Padriciano 99, 34149, Trieste, Italy
| | - Brian McGuinness
- Crescendo Biologics Ltd, Babraham Research Campus, Cambridge, CB22 3AT, UK
| | - Thomas Sandal
- Crescendo Biologics Ltd, Babraham Research Campus, Cambridge, CB22 3AT, UK
| | - Mike Romanos
- Crescendo Biologics Ltd, Babraham Research Campus, Cambridge, CB22 3AT, UK
| |
Collapse
|
4
|
Strategies to Obtain Diverse and Specific Human Monoclonal Antibodies From Transgenic Animals. Transplantation 2017; 101:1770-1776. [DOI: 10.1097/tp.0000000000001702] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
5
|
Brüggemann M, Osborn MJ, Ma B, Hayre J, Avis S, Lundstrom B, Buelow R. Human antibody production in transgenic animals. Arch Immunol Ther Exp (Warsz) 2014; 63:101-8. [PMID: 25467949 PMCID: PMC4359279 DOI: 10.1007/s00005-014-0322-x] [Citation(s) in RCA: 85] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2014] [Accepted: 11/19/2014] [Indexed: 11/26/2022]
Abstract
Fully human antibodies from transgenic animals account for an increasing number of new therapeutics. After immunization, diverse human monoclonal antibodies of high affinity can be obtained from transgenic rodents, while large animals, such as transchromosomic cattle, have produced respectable amounts of specific human immunoglobulin (Ig) in serum. Several strategies to derive animals expressing human antibody repertoires have been successful. In rodents, gene loci on bacterial artificial chromosomes or yeast artificial chromosomes were integrated by oocyte microinjection or transfection of embryonic stem (ES) cells, while ruminants were derived from manipulated fibroblasts with integrated human chromosome fragments or human artificial chromosomes. In all strains, the endogenous Ig loci have been silenced by gene targeting, either in ES or fibroblast cells, or by zinc finger technology via DNA microinjection; this was essential for optimal production. However, comparisons showed that fully human antibodies were not as efficiently produced as wild-type Ig. This suboptimal performance, with respect to immune response and antibody yield, was attributed to imperfect interaction of the human constant region with endogenous signaling components such as the Igα/β in mouse, rat or cattle. Significant improvements were obtained when the human V-region genes were linked to the endogenous CH-region, either on large constructs or, separately, by site-specific integration, which could also silence the endogenous Ig locus by gene replacement or inversion. In animals with knocked-out endogenous Ig loci and integrated large IgH loci, containing many human Vs, all D and all J segments linked to endogenous C genes, highly diverse human antibody production similar to normal animals was obtained.
Collapse
Affiliation(s)
- Marianne Brüggemann
- Recombinant Antibody Technology Ltd., Babraham Research Campus, Babraham, Cambridge CB22 3AT UK
- Open Monoclonal Technology, Inc., Palo Alto, CA 94303 USA
| | - Michael J. Osborn
- Recombinant Antibody Technology Ltd., Babraham Research Campus, Babraham, Cambridge CB22 3AT UK
| | - Biao Ma
- Recombinant Antibody Technology Ltd., Babraham Research Campus, Babraham, Cambridge CB22 3AT UK
| | - Jasvinder Hayre
- Recombinant Antibody Technology Ltd., Babraham Research Campus, Babraham, Cambridge CB22 3AT UK
| | - Suzanne Avis
- Recombinant Antibody Technology Ltd., Babraham Research Campus, Babraham, Cambridge CB22 3AT UK
| | | | - Roland Buelow
- Open Monoclonal Technology, Inc., Palo Alto, CA 94303 USA
| |
Collapse
|
6
|
Immunoglobulin aggregation leading to Russell body formation is prevented by the antibody light chain. Blood 2009; 115:282-8. [PMID: 19822901 DOI: 10.1182/blood-2009-07-234864] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
Russell bodies (RBs) are intracellular inclusions filled with protein aggregates. In diverse lymphoid disorders these occur as immunoglobulin (Ig) deposits, accumulating in abnormal plasma or Mott cells. In heavy-chain deposition disease truncated antibody heavy-chains (HCs) are found, which bear a resemblance to diverse polypeptides produced in Ig light-chain (LC)-deficient (L(-/-)) mice. In L(-/-) animals, the known functions of LC, providing part of the antigen-binding site of an antibody and securing progression of B-cell development, may not be required. Here, we show a novel function of LC in preventing antibody aggregation. L(-/-) mice produce truncated HC naturally, constant region (C)gamma and Calpha lack C(H)1, and Cmicro is without C(H)1 or C(H)1 and C(H)2. Most plasma cells found in these mice are CD138(+) Mott cells, filled with RBs, formed by aggregation of HCs of different isotypes. The importance of LC in preventing HC aggregation is evident in knock-in mice, expressing Cmicro without C(H)1 and C(H)2, which only develop an abundance of RBs when LC is absent. These results reveal that preventing antibody aggregation is a major function of LC, important for understanding the physiology of heavy-chain deposition disease, and in general recognizing the mechanisms, which initiate protein conformational diseases.
Collapse
|
7
|
Matheson LS, Osborn MJ, Smith JA, Corcos D, Hamon M, Chaouaf R, Coadwell J, Morgan G, Oxley D, Brüggemann M. Light chain-deficient mice produce novel multimeric heavy-chain-only IgA by faulty class switching. Int Immunol 2009; 21:957-66. [PMID: 19561045 DOI: 10.1093/intimm/dxp062] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
Recently, we identified that diverse heavy chain (H-chain)-only IgG is spontaneously produced in light chain (L-chain)-deficient mice (L(-/-) with silenced kappa and lambda loci) despite a block in B cell development. In murine H-chain IgG, the first Cgamma exon, C(H)1, is removed after DNA rearrangement and secreted polypeptides are comparable with camelid-type H-chain IgG. Here we show that L(-/-) mice generate a novel class of H-chain Ig with covalently linked alpha chains, not identified in any other healthy mammal. Surprisingly, diverse H-chain-only IgA can be released from B cells at levels similar to conventional IgA and is found in serum and sometimes in milk and saliva. Surface IgA without L-chain is expressed in B220(+) spleen cells, which exhibited a novel B cell receptor, suggesting that associated conventional differentiation events occur. To facilitate the cellular transport and release of H-chain-only IgA, chaperoning via BiP association seems to be prevented as only alpha chains lacking C(H)1 are released from the cell. This appears to be accomplished by imprecise class-switch recombination (CSR) from Smu into the alpha constant region, which removes all or part of the Calpha1 exon at the genomic level.
Collapse
|
8
|
Zou X, Osborn MJ, Bolland DJ, Smith JA, Corcos D, Hamon M, Oxley D, Hutchings A, Morgan G, Santos F, Kilshaw PJ, Taussig MJ, Corcoran AE, Brüggemann M. Heavy chain-only antibodies are spontaneously produced in light chain-deficient mice. J Exp Med 2007; 204:3271-83. [PMID: 18086860 PMCID: PMC2150980 DOI: 10.1084/jem.20071155] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2007] [Accepted: 11/20/2007] [Indexed: 12/18/2022] Open
Abstract
In healthy mammals, maturation of B cells expressing heavy (H) chain immunoglobulin (Ig) without light (L) chain is prevented by chaperone association of the H chain in the endoplasmic reticulum. Camelids are an exception, expressing homodimeric IgGs, an antibody type that to date has not been found in mice or humans. In camelids, immunization with viral epitopes generates high affinity H chain-only antibodies, which, because of their smaller size, recognize clefts and protrusions not readily distinguished by typical antibodies. Developmental processes leading to H chain antibody expression are unknown. We show that L(-/-) (kappa(-/-)lambda(-/-)-deficient) mice, in which conventional B cell development is blocked at the immature B cell stage, produce diverse H chain-only antibodies in serum. The generation of H chain-only IgG is caused by the loss of constant (C) gamma exon 1, which is accomplished by genomic alterations in C(H)1-circumventing chaperone association. These mutations can be attributed to errors in class switch recombination, which facilitate the generation of H chain-only Ig-secreting plasma cells. Surprisingly, transcripts with a similar deletion can be found in normal mice. Thus, naturally occurring H chain transcripts without C(H)1 (V(H)DJ(H)-hinge-C(H)2-C(H)3) are selected for and lead to the formation of fully functional and diverse H chain-only antibodies in L(-/-) animals.
Collapse
Affiliation(s)
- Xiangang Zou
- The Babraham Institute, Babraham, Cambridge CB22 3AT, England, UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Abstract
Laboratory mice provide a ready source of diverse, high-affinity and high-specificity monoclonal antibodies (mAbs). However, development of rodent antibodies as therapeutic agents has been impaired by the inherent immunogenicity of these molecules. One technology that has been explored to generate low immunogenicity mAbs for in vivo therapy involves the use of transgenic mice expressing repertoires of human antibody gene sequences. This technology has now been exploited by over a dozen different pharmaceutical and biotechnology companies toward developing new therapeutic mAbs, and currently at least 33 different drugs in clinical testing--including several in pivotal trials--contain variable regions encoded by human sequences from transgenic mice. The emerging data from these trials provide an early glimpse of the safety and efficacy issues for these molecules. Nevertheless, actual product approval, the biggest challenge so far, is required to fully validate this technology as a drug discovery tool. In the future, it may be possible to extend this technology beyond rodents and use transgenic farm animals to directly generate and produce human sequence polyclonal sera.
Collapse
Affiliation(s)
- Nils Lonberg
- Medarex, 521 Cottonwood Drive, Milpitas, California 95035, USA.
| |
Collapse
|
10
|
Zou X, Smith JA, Nguyen VK, Ren L, Luyten K, Muyldermans S, Brüggemann M. Expression of a Dromedary Heavy Chain-Only Antibody and B Cell Development in the Mouse. THE JOURNAL OF IMMUNOLOGY 2005; 175:3769-79. [PMID: 16148123 DOI: 10.4049/jimmunol.175.6.3769] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Abstract
In mature B cells of mice and most mammals, cellular release of single H chain Abs without L chains is prevented by H chain association with Ig-specific chaperons in the endoplasmic reticulum. In precursor B cells, however, surface expression of mu-H chain in the absence of surrogate and conventional L chain has been identified. Despite this, Ag-specific single H chain Ig repertoires, using mu-, gamma-, epsilon-, or alpha-H chains found in conventional Abs, are not produced. Moreover, removal of H chain or, separately, L chain (kappa/lambda) locus core sequences by gene targeting has prevented B cell development. In contrast, H chain-only Abs are produced abundantly in Camelidae as H2 IgG without the C(H)1 domain. To test whether H chain Abs can be produced in mice, and to investigate how their expression affects B cell development, we introduced a rearranged dromedary gamma2a H chain into the mouse germline. The dromedary transgene was expressed as a naturally occurring Ag-specific disulphide-linked homodimer, which showed that B cell development can be instigated by expression of single H chains without L chains. Lymphocyte development and B cell proliferation was accomplished despite the absence of L chain from the BCR complex. Endogenous Ig could not be detected, although V(D)J recombination and IgH/L transcription was unaltered. Furthermore, crossing the dromedary H chain mice with mice devoid of all C genes demonstrated without a doubt that a H chain-only Ab can facilitate B cell development independent of endogenous Ig expression, such as mu- or delta-H chain, at early developmental stages.
Collapse
Affiliation(s)
- Xiangang Zou
- Protein Technologies Laboratory, The Babraham Institute, Babraham, Cambridge, United Kingdom
| | | | | | | | | | | | | |
Collapse
|